DaVita Inc. (NYSE:DVA) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 27.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,321 shares of the company's stock after selling 41,487 shares during the period. Schroder Investment Management Group owned about 0.14% of DaVita worth $16,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in DaVita during the 4th quarter valued at about $41,000. Quarry LP acquired a new position in DaVita during the third quarter worth $60,000. Venturi Wealth Management LLC increased its stake in shares of DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after purchasing an additional 131 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on DVA. StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a report on Wednesday, April 2nd. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Stock Performance

DVA traded down $2.98 on Tuesday, reaching $143.63. The company had a trading volume of 904,702 shares, compared to its average volume of 816,972. The stock has a 50-day moving average price of $153.98 and a 200-day moving average price of $156.84. The stock has a market capitalization of $11.49 billion, a PE ratio of 13.37, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.